To learn more about the top medical innovations for 2022, please visit [ Ссылка ]
In the United States, 1 in 10 individuals has diabetes, which affects how the body processes food into energy. One potential therapy is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) that aims to control blood sugar. Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal. Additionally, it slows digestion, resulting in individuals remaining full longer and eating less. Thus far, late phase III clinical trials reveal that the treatment significantly reduces hemoglobin A1C in type 2 diabetes and supports weight loss, making it potentially the most effective therapy for diabetes and obesity yet developed.
▶Share this video with others: [ Ссылка ]
▶Subscribe to learn more about Cleveland Clinic:
[ Ссылка ]
#ClevelandClinic #MedicalInnovations
Novel Drug for Treatment of Type 2 Diabetes
Теги
medical innovations 2022cleveland clinic innovationstop 10 medical innovationsmedical innovations from cleveland clinicmedical innovationstop 10 medical innovation 2022top 10 medical innovation cleveland clinic4219cleveland clinicthe top 10 most promising medical technologiesinsulinotropic polypeptide (gip)glucagon like peptide 1gip for type 2 diabetesglp 1 diabetesnew type 2 diabetes medicationsglp-1 and gip receptors